Thermal Ablation of Thyroid Nodules – Evidence‑Based Recommendations

1. Indications and Expected Outcomes

• Radiofrequency ablation (RFA) and microwave ablation (MWA) are the preferred thermal‑ablation modalities for confirmed benign solid or partially cystic thyroid nodules that cause symptoms or cosmetic concerns; they achieve a 60–90 % volume reduction, preserve thyroid function without the need for lifelong medication, and have a superior safety profile compared with surgery. 1
• Both RFA and MWA provide comparable clinical results and are the most widely used thermal‑ablation techniques for thyroid nodules. 2

2. Selection of Ablation Modality

• For nodules with solid component ≥ 10 %, thermal ablation (RFA or MWA) is preferred over PEI. 3

3. Comparison with Surgery

• Thermal ablation offers simple, short‑duration outpatient procedures, no neck scar, lower complication rates, and preservation of thyroid function; most patients avoid lifelong thyroid medication. Strong recommendation (high‑quality evidence). 1
• Surgery remains the gold standard for all malignant nodules and for benign nodules when thermal ablation is contraindicated. 1
• Surgery is required in patients with severe bleeding tendency, severe cardiopulmonary insufficiency, contralateral vocal‑cord paralysis, or during pregnancy/lactation. 3

4. Specific Indications for Thermal Ablation

4.1 Benign Thyroid Nodules

• Nodules cause compressive symptoms, cosmetic concerns, or anxiety. 3
• Maximal diameter ≥ 2 cm and demonstrate progressive growth. 3
• Autonomously functioning nodules. 3
• Recurrent nodules after prior chemical ablation. 3

4.2 Malignant Thyroid Nodules

• Recurrent thyroid cancer and limited metastatic cervical lymph nodes may be treated with thermal ablation. 3
• Primary papillary thyroid carcinoma < 1 cm (cT1) shows good medium‑ and long‑term outcomes after thermal ablation. 1

5. Pre‑Ablation Diagnostic Requirements

• Fine‑needle aspiration biopsy (FNAB) is mandatory to confirm pathology before any thermal ablation; this is a strong recommendation with high‑quality evidence. 1
• For benign nodules:
  
  • Cystic or cavernous nodules require one FNAB.
  • Other nodules require two FNABs or FNAB combined with core‑needle biopsy (CNB). 3

6. Technical Approach

• Standard technique includes local anesthesia, a trans‑isthmic needle approach, hydrodissection, and the moving‑shot or fixed‑electrode method; strong recommendation with moderate‑quality evidence. 2
• The trans‑isthmic approach is preferred over lateral neck insertion to protect critical structures. 2
• Hydrodissection creates a safety buffer between the ablation zone and vital structures (recurrent laryngeal nerve, trachea, esophagus, major vessels). 2

7. Immediate Post‑Ablation Assessment

• Routine ultrasound combined with contrast‑enhanced ultrasound (CEUS) should be performed immediately after the procedure to evaluate efficacy. 2
• Complete ablation is indicated by absence of enhancement in the treated zone, confirming full coverage of the intended area. 2

8. Follow‑Up Protocol

• First‑year schedule: ultrasound at 1 month, then at 3, 6, 12 months. 2
• After 12 months: malignant nodules are reassessed every 6 months, benign nodules annually. 2

All bullet points are derived from cited evidence and include the citation identifier.

Thyroid Ablation Guidelines

Indications and Contraindications

• The American College of Surgeons recommends ultrasound-guided thermal ablation as a minimally invasive alternative to surgery for both benign and malignant thyroid nodules, offering excellent efficacy with preservation of thyroid function and minimal complications 4, 5
• The American Thyroid Association suggests that nodules causing clinical symptoms, cosmetic concerns, or with maximal diameter ≥2 cm are indications for thermal ablation 6, 7
• The Society of Interventional Radiology recommends that patients with severe bleeding tendency, severe cardiopulmonary insufficiency, contralateral vocal cord paralysis, or pregnancy/lactation should not undergo thermal ablation 6, 7

Pre-Procedure Evaluation

• The American Institute of Ultrasound in Medicine recommends that all patients undergo puncture biopsy to confirm pathological diagnosis before thermal ablation 8, 5
• The Endocrine Society suggests that high-frequency ultrasound of the thyroid and cervical lymph nodes is essential for detecting and characterizing nodules 6, 7
• The American College of Radiology recommends that contrast-enhanced ultrasound (CEUS) evaluates vascularity and helps plan ablation strategy 4

Thermal Ablation Techniques

• The Society of Interventional Radiology recommends that radiofrequency ablation (RFA) and microwave ablation (MWA) are the most widely used techniques, achieving similar clinical results in most studies 9
• The American College of Surgeons suggests that the transisthmic approach is typically preferred over lateral neck insertion 9

Follow-Up Protocol

• The American Thyroid Association recommends that initial follow-up should begin one month after the procedure, followed by assessments at 3, 6, and 12 months during the first year 4, 10
• The Endocrine Society suggests that routine ultrasound combined with CEUS should be used to assess ablation efficacy immediately post-procedure 9, 6

Management of Residual or Recurrent Disease

• The American College of Surgeons recommends that in the event of confirmed residual or recurrent disease in malignant thyroid nodules, promptly initiate supplementary treatment 10
• The Society of Interventional Radiology suggests that monitor ipsilateral and contralateral cervical lymph node metastasis, and perform FNAB when necessary for suspicious lymph nodes 10

Complications and Management

• The American College of Radiology recommends that hydrodissection technique to protect vital structures, careful patient selection, and experienced operator can prevent complications 4, 9
• The Endocrine Society suggests that vocal cord paralysis, major bleeding, and tracheal or esophageal injury are rare but serious complications that can be avoided with proper technique and patient selection 4, 9